Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients

NCT: NCT07536516 · RECRUITING

NCT IDNCT07536516
StatusRECRUITING
Start Date2025-11-28
Completion2026-06-01

Brief Summary

The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.

Frequently Asked Questions

What is Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients?

Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients is a clinical trial registered under NCT07536516. Current status: RECRUITING.

What is the status of NCT07536516?

The current status of NCT07536516 (Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients) is: RECRUITING.

When did Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients start?

Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients started on 2025-11-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑